The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 10214759.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The fate of the neutralizing antibody (NAB) in MS patients treated with interferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon alpha-1b. NAB were measured with the myxovirus protein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.
Medical subject headings
- Antigen-Antibody Reactions
- Interferon-beta
- Multiple Sclerosis